Lifecore Biomedical adopts new incentive bonus plan

Lifecore Biomedical, Inc. reported that its Compensation Committee approved and adopted a new Incentive Bonus Plan effective January 14, 2026.

Rhea-AI Filing Summary

Lifecore Biomedical, Inc. reported that its Compensation Committee approved and adopted a new Incentive Bonus Plan effective January 14, 2026. The plan covers executive officers and certain other employees chosen by the committee and provides for cash bonus payments based on achieving financial and other performance targets.

The committee has broad authority under the plan to select participants, set performance periods, choose and weight performance goals, determine bonus amounts, link payouts to the level of goal achievement, and adjust awards for unusual events such as acquisitions or divestitures. The full text of the Incentive Bonus Plan is filed as Exhibit 10.1 to the report.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lifecore Biomedical (LFCR) announce in this 8-K filing?

Lifecore Biomedical reported that its Compensation Committee approved and adopted a new Incentive Bonus Plan effective January 14, 2026, governing cash bonus awards.

Who is eligible under Lifecore Biomedical's new Incentive Bonus Plan?

Executive officers and certain other employees of Lifecore Biomedical selected by the Compensation Committee are eligible to participate in the Incentive Bonus Plan.

How are bonuses determined under the Lifecore Biomedical Incentive Bonus Plan?

Bonuses are paid in cash and are based on achieving financial and other performance targets established by the Compensation Committee, including the weighting of those targets and the level of achievement.

What authority does the Compensation Committee have under the Lifecore Biomedical plan?

The committee can designate participants, set performance periods, determine bonus amounts, select and weight performance targets, define the link between performance and payouts, and adjust bonuses for unusual events like acquisitions or divestitures.

Where can investors find the full details of Lifecore Biomedical's Incentive Bonus Plan?

The complete text of the Incentive Bonus Plan is filed as Exhibit 10.1 to the report and is incorporated by reference.

When did Lifecore Biomedical's Incentive Bonus Plan become effective?

The Incentive Bonus Plan became effective on January 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/16/2026 - 04:29 PM Learn about SEC filing dates

FALSE000100528600010052862026-01-142026-01-14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2026

LIFECORE BIOMEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-27446

94-3025618

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)

3515 Lyman Boulevard
Chaska,			Minnesota			55318
(Address of principal executive offices)						(Zip Code)

(952) 368-4300

(Registrant’s telephone number, including area code)

 Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common stock, par value $0.001 per share

LFCR

The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of

Certain Officers; Compensatory Arrangements of Certain Officers.

On January 14, 2026, the Compensation Committee of the Board of Directors of Lifecore Biomedical, Inc. (the “Company”) approved and adopted the Lifecore Biomedical, Inc. Incentive Bonus Plan (the “Plan”) effective January 14, 2026 (the “Effective Date”) for bonus awards granted on or after the Effective Date. The Plan provides for a cash payment to be made to the executive officers and certain other employees of the Company selected for participation in the Plan, based upon the achievement of certain financial and other performance targets established by the Compensation Committee. The Compensation Committee has the authority to designate the participants in the Plan; determine the applicable performance period; determine the amount of each bonus award; select applicable performance targets; identify the weights of applicable performance targets; determine the relationship between the degree to which performance targets have been achieved and bonus payments; and adjust bonus payments based on unusual or unique circumstances or the impact of acquisitions, divestitures or other major unusual events.

The foregoing summary of the Plan does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Plan, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

10.1

Lifecore Biomedical, Inc. Incentive Bonus Plan effective January 14, 2026

104

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 16, 2026

			LIFECORE BIOMEDICAL, INC.
By:			/s/ Ryan D. Lake
			Ryan D. Lake
			Chief Financial Officer